DefinitionThis section has been translated automatically.
5-HT3 antagonist, antiemetic.
Pharmacodynamics (Effect)This section has been translated automatically.
Selective, competitive binding to 5-HT3 receptors in the brain and elsewhere. As a result, serotonin can no longer bind to its binding sites on the 5-HT3 receptors and develop its effect. This directly prevents the development of nausea and vomiting, for example.
You might also be interested in
IndicationThis section has been translated automatically.
Nausea and vomiting during therapy with cytostatic drugs or radiation therapy.
Dosage and method of useThis section has been translated automatically.
- Adults: 1 time per day 2 mg p.o. or 1-3 mg slow i.v. Alternatively 1 time per day 0.01 mg/kg bw slow i.v. If necessary, the dosage can be repeated 1-2 times per day.
- Children > 2 years and < 25 kg kg kg: 1 time / day 40 μg/kg kg kg slow i.v. If necessary, the dosage can be repeated 1-2 times / day.
- Children > 2 yrs and > 25 kg bw: 1 time a day 1 mg slow i.v. If necessary, the dosage can be repeated 1-2 times a day.
Undesirable effectsThis section has been translated automatically.
- Cutaneous ADRs: Rare hypersensitivity reactions, occasionally anaphylactoid reactions. Slight rashes and very rarely edema, especially facial edema. Local reactions at the infusion site.
- Extracutaneous ADRs: mild to moderate headache and constipation of low or moderate severity. Temporary increase in transaminases. Occasional flu-like symptoms with fever and chills. Rarely chest pain or shortness of breath. Local reactions at the infusion site.
ContraindicationThis section has been translated automatically.
Use in children < 2 years, hypersensitivity reactions to other 5-HT3 antagonists.
PreparationsThis section has been translated automatically.
Kevatril
Prof. Dr. med. Peter Altmeyer